Jin Zhong

List of Publications by Year in Descending Order

106 papers	5,074 citations	30 h-index	70 g-index
111 ext. papers	5,757 ext. citations	8.2 avg, IF	5.29 L-index

#	Paper	IF	Citations
106	Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.. *MBio*, **2022**, e0009922	7.8	3
105	Mouse circulating extracellular vesicles contain virus-derived siRNAs active in antiviral immunity.. *EMBO Journal*, **2022**, e109902	13	1
104	Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption. *PLoS Pathogens*, **2021**, 17, e1010053	7.6	6
103	Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance. *Antiviral Research*, **2021**, 197, 105224	10.8	0
102	A novel cell culture system modeling the SARS-CoV-2 life cycle. *PLoS Pathogens*, **2021**, 17, e1009439	7.6	33
101	Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry. *PLoS Pathogens*, **2021**, 17, e1009392	7.6	16
100	UNC93B1 curbs cytosolic DNA signaling by promoting STING degradation. *European Journal of Immunology*, **2021**, 51, 1672-1685	6.1	4
99	Development of a New Reverse Genetics System for Ebola Virus. *MSphere*, **2021**, 6,	5	1
98	Photo-catalyzed TiO inactivates pathogenic viruses by attacking viral genome. *Chemical Engineering Journal*, **2021**, 414, 128788	14.7	16
97	Junctional and somatic hypermutation-induced CXC motif is critical for the recognition of a highly conserved epitope on HCV E2 by a human broadly neutralizing antibody. *Cellular and Molecular Immunology*, **2021**, 18, 675-685	15.4	4
96	TRIM26 is a critical host factor for HCV replication and contributes to host tropism. *Science Advances*, **2021**, 7,	14.3	7
95	Inhibitor Development against p7 Channel in Hepatitis C Virus. *Molecules*, **2021**, 26,	4.8	2
94	Hepatitis C virus genotype 4: A poorly characterized endemic genotype. *Journal of Medical Virology*, **2021**, 93, 6079-6088	19.7	2
93	Glycometabolism regulates hepatitis C virus release. *PLoS Pathogens*, **2021**, 17, e1009746	7.6	1
92	Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. *Antiviral Research*, **2021**, 194, 105161	10.8	1
91	A Nanoparticle-Based Hepatitis C Virus Vaccine With Enhanced Potency. *Journal of Infectious Diseases*, **2020**, 221, 1304-1314	7	24
90	Multifaceted Functions of Host Cell Caveolae/Caveolin-1 in Virus Infections. *Viruses*, **2020**, 12,	6.2	20

89	IL-1Enhances the Antiviral Effect of IFN-bn HCV Replication by Negatively Modulating ERK2 Activation. *ACS Infectious Diseases*, **2020**, 6, 1708-1718	5.5	3
88	An Alternative Splicing of STING Modulated Anti-RNA Virus Responses by Targeting MDA5-LGP2 and IRF3. *Journal of Immunology*, **2020**, 204, 3191-3204	5.3	11
87	Anti-flavivirus activity of polyoxometalate. *Antiviral Research*, **2020**, 179, 104813	10.8	8
86	A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution. *Journal of Virology*, **2020**, 94,	6.6	2
85	Small Molecule Inhibitor of ATPase Activity of HSP70 as a Broad-Spectrum Inhibitor against Flavivirus Infections. *ACS Infectious Diseases*, **2020**, 6, 832-843	5.5	16
84	The pre-existing cellular immunity to Japanese encephalitis virus heterotypically protects mice from Zika virus infection. *Science Bulletin*, **2020**, 65, 402-409	10.6	5
83	MAVS Is a Dual Target during Hepatitis C Virus Infection for Innate Immune Evasion and Viral Replication via NF-B. *Journal of Immunology*, **2020**, 205, 2091-2099	5.3	7
82	ZIKV infection induces robust Th1-like Tfh cell and long-term protective antibody responses in immunocompetent mice. *Nature Communications*, **2019**, 10, 3859	17.4	20
81	Antiviral effects of simeprevir on multiple viruses. *Antiviral Research*, **2019**, 172, 104607	10.8	7
80	Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus. *PLoS Pathogens*, **2019**, 15, e1007759	7.6	15
79	Ebola virus VP35has novel NTPase and helicase-like activities. *Nucleic Acids Research*, **2019**, 47, 5837-5851	10.1	15
78	Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. *Antiviral Research*, **2019**, 171, 104612	10.8	4
77	A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. *Gut*, **2019**, 68, 140-149	19.2	20
76	Insect cell-produced recombinant protein subunit vaccines protect against Zika virus infection. *Antiviral Research*, **2018**, 154, 97-103	10.8	20
75	Antiviral effects of ferric ammonium citrate. *Cell Discovery*, **2018**, 4, 14	22.3	22
74	Genetic Analysis of Serum-Derived Defective Hepatitis C Virus Genomes Revealed Novel Viral Elements for Virus Replication and Assembly. *Journal of Virology*, **2018**, 92,	6.6	7
73	MLL5 suppresses antiviral innate immune response by facilitating STUB1-mediated RIG-I degradation. *Nature Communications*, **2018**, 9, 1243	17.4	18
72	Identification of nucleotides in the 5UTR and amino acids substitutions that are essential for the infectivity of 5UTR-NS5A recombinant of hepatitis C virus genotype 1b (strain Con1). *Virology*, **2018**, 518, 253-263	3.6	6

71	Celastrol specifically inhibits the activation of NLRP3 inflammasome. *Science China Life Sciences*, **2018**, 61, 355-357	8.5	6
70	Role of Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. *Frontiers in Immunology*, **2018**, 9, 1411	8.4	22
69	Negligible contribution of M2634V substitution to ZIKV pathogenesis in AG6 mice revealed by a bacterial promoter activity reduced infectious clone. *Scientific Reports*, **2018**, 8, 10491	4.9	15
68	Neuralized E3 Ubiquitin Protein Ligase 3 Is an Inducible Antiviral Effector That Inhibits Hepatitis C Virus Assembly by Targeting Viral E1 Glycoprotein. *Journal of Virology*, **2018**, 92,	6.6	3
67	Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway. *PLoS Pathogens*, **2018**, 14, e1007075	7.6	22
66	A Point Mutation in the N-Terminal Amphipathic Helix In NS3 Promotes Hepatitis C Virus Assembly by Altering Core Localization to the Endoplasmic Reticulum and Facilitating Virus Budding. *Journal of Virology*, **2017**, 91,	6.6	11
65	Laboratory of genetics and physiology 2 (LGP2) plays an essential role in hepatitis C virus infection-induced interferon responses. *Hepatology*, **2017**, 65, 1478-1491	11.2	21
64	Functional Analysis of Hepatitis C Virus (HCV) Envelope Protein E1 Using a -Complementation System Reveals a Dual Role of a Putative Fusion Peptide of E1 in both HCV Entry and Morphogenesis. *Journal of Virology*, **2017**, 91,	6.6	18
63	Immunization With a Subunit Hepatitis C Virus Vaccine Elicits Pan-Genotypic Neutralizing Antibodies and Intrahepatic T-Cell Responses in Nonhuman Primates. *Journal of Infectious Diseases*, **2017**, 215, 1824-1831	7	17
62	A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. *Antiviral Research*, **2017**, 139, 18-24	10.8	3
61	Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance. *PLoS ONE*, **2017**, 12, e0171217	3.7	14
60	Novel Stable Ebola Virus Minigenome Replicon Reveals Remarkable Stability of the Viral Genome. *Journal of Virology*, **2017**, 91,	6.6	11
59	Pediatric Drug Nitazoxanide: A Potential Choice for Control of Zika. *Open Forum Infectious Diseases*, **2017**, 4, ofx009	1	28
58	Neglected but Important Role of Apolipoprotein E Exchange in Hepatitis C Virus Infection. *Journal of Virology*, **2016**, 90, 9632-9643	6.6	30
57	Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice. *Journal of Virology*, **2016**, 90, 10486-10498	6.6	48
56	Interferon alpha (IFN)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A. *Cellular and Molecular Immunology*, **2016**, 13, 94-102	15.4	61
55	IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection. *Infection, Genetics and Evolution*, **2016**, 39, 132-140	4.5	7
54	IFN- desensitizes the response to IFN- treatment in chronic hepatitis C through long-term induction of USP18. *Journal of General Virology*, **2016**, 97, 2210-2220	4.9	16

53	Innate immunity against hepatitis C virus. *Current Opinion in Immunology*, **2016**, 42, 98-104	7.8	25
52	Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. *Scientific Reports*, **2016**, 6, 25224	4.9	8
51	Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients. *Journal of Gastroenterology and Hepatology (Australia)*, **2016**, 31, 1489-97	4	2
50	Total synthesis and antiviral activity of indolosesquiterpenoids from the xiamycin and oridamycin families. *Nature Communications*, **2015**, 6, 6096	17.4	95
49	Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus Infection. *Journal of Virology*, **2015**, 89, 6805-16	6.6	61
48	Casein kinase II controls TBK1/IRF3 activation in IFN response against viral infection. *Journal of Immunology*, **2015**, 194, 4477-88	5.3	28
47	CD24 Ala57Val polymorphism is associated with spontaneous viral clearance in the HCV-infected Chinese population. *Liver International*, **2015**, 35, 786-94	7.9	4
46	Hepatitis C virus vaccine development: old challenges and new opportunities. *National Science Review*, **2015**, 2, 285-295	10.8	22
45	Tuberous Sclerosis Complex Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38. *Journal of Virology*, **2015**, 89, 7625-35	6.6	10
44	MDA5 plays a critical role in interferon response during hepatitis C virus infection. *Journal of Hepatology*, **2015**, 62, 771-8	13.4	70
43	Use of parenteral caffeinum natrio-benzoicum: an underestimated risk factor for HCV transmission in China. *BMC Public Health*, **2015**, 15, 928	4.1	9
42	IL28B is associated with outcomes of chronic HBV infection. *Yonsei Medical Journal*, **2015**, 56, 625-33	3	8
41	The hepatitis C virus protein NS3 suppresses TNF-□stimulated activation of NF-B by targeting LUBAC. *Science Signaling*, **2015**, 8, ra118	8.8	30
40	Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma. *PLoS ONE*, **2015**, 10, e0127518	3.7	55
39	Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population. *PLoS ONE*, **2015**, 10, e0139015	3.7	23
38	Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. *Scientific Reports*, **2014**, 4, 7242	4.9	72
37	Long-term effect on natural killer cells by interferon-□therapy on the outcomes of HCV infection. *Journal of Interferon and Cytokine Research*, **2014**, 34, 366-75	3.5	7
36	Human NLRP3 inflammasome senses multiple types of bacterial RNAs. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 16059-64	11.5	77

35	Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape. *Journal of Immunology*, **2014**, 193, 783-96	5.3	45
34	Factors associated with spontaneous clearance of hepatitis C virus in Chinese population. *BioMed Research International*, **2014**, 2014, 527030	3	12
33	A novel strategy to develop a robust infectious hepatitis C virus cell culture system directly from a clinical isolate. *Journal of Virology*, **2014**, 88, 1484-91	6.6	23
32	HCV genomic RNA activates the NLRP3 inflammasome in human myeloid cells. *PLoS ONE*, **2014**, 9, e84953	3.7	60
31	DDB1 is a cellular substrate of NS3/4A protease and required for hepatitis C virus replication. *Virology*, **2013**, 435, 385-94	3.6	17
30	Inhibition of hepatitis C virus infection by polyoxometalates. *Antiviral Research*, **2013**, 100, 392-8	10.8	28
29	Construction and characterization of infectious hepatitis C virus chimera containing structural proteins directly from genotype 1b clinical isolates. *Virology*, **2013**, 443, 80-8	3.6	16
28	Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. *Journal of Hepatology*, **2013**, 59, 52-8	13.4	119
27	Negative regulation of interferon-induced transmembrane protein 3 by SET7-mediated lysine monomethylation. *Journal of Biological Chemistry*, **2013**, 288, 35093-103	5.4	25
26	Mycoplasma hyorhinis activates the NLRP3 inflammasome and promotes migration and invasion of gastric cancer cells. *PLoS ONE*, **2013**, 8, e77955	3.7	42
25	The N-terminal helix (0) of hepatitis C virus NS3 protein dictates the subcellular localization and stability of NS3/NS4A complex. *Virology*, **2012**, 422, 214-23	3.6	13
24	Hepatitis C virus NS3/4A protease blocks IL-28 production. *European Journal of Immunology*, **2012**, 42, 2374-82	6.1	32
23	IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. *PLoS ONE*, **2012**, 7, e37054	3.7	75
22	An integrated transcriptomic and meta-analysis of hepatoma cells reveals factors that influence susceptibility to HCV infection. *PLoS ONE*, **2011**, 6, e25584	3.7	15
21	Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment. *Infection, Genetics and Evolution*, **2011**, 11, 382-90	4.5	8
20	Production of hepatitis C virus lacking the envelope-encoding genes for single-cycle infection by providing homologous envelope proteins or vesicular stomatitis virus glycoproteins in trans. *Journal of Virology*, **2011**, 85, 2138-47	6.6	17
19	Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 3355-64	5.9	7
18	Sphingomyelin activates hepatitis C virus RNA polymerase in a genotype-specific manner. *Journal of Virology*, **2010**, 84, 11761-70	6.6	57

17	A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles. *Virology*, **2009**, 395, 67-76	3.6	48
16	Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. *Journal of General Virology*, **2008**, 89, 1225-1230	4.9	90
15	Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. *Journal of Virology*, **2008**, 82, 2120-9	6.6	363
14	Negative regulation of virus-triggered IFN-beta signaling pathway by alternative splicing of TBK1. *Journal of Biological Chemistry*, **2008**, 283, 35590-7	5.4	37
13	Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. *Journal of Virology*, **2008**, 82, 12020-9	6.6	137
12	Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 9035-40	11.5	125
11	Persistent hepatitis C virus infection in vitro: coevolution of virus and host. *Journal of Virology*, **2006**, 80, 11082-93	6.6	218
10	Use of targetrons to disrupt essential and nonessential genes in Staphylococcus aureus reveals temperature sensitivity of Ll.LtrB group II intron splicing. *Rna*, **2006**, 12, 1271-81	5.8	81
9	Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 8499-504	11.5	111
8	Gene targeting using randomly inserted group II introns (targetrons) recovered from an Escherichia coli gene disruption library. *Nucleic Acids Research*, **2005**, 33, 3351-62	20.1	24
7	Robust hepatitis C virus infection in vitro. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 9294-9	11.5	1481
6	Recruitment of host functions suggests a repair pathway for late steps in group II intron retrohoming. *Genes and Development*, **2005**, 19, 2477-87	12.6	62
5	Group II intron mobility using nascent strands at DNA replication forks to prime reverse transcription. *EMBO Journal*, **2003**, 22, 4555-65	13	70
4	Targeted and random bacterial gene disruption using a group II intron (targetron) vector containing a retrotransposition-activated selectable marker. *Nucleic Acids Research*, **2003**, 31, 1656-64	20.1	113
3	Mutations in the Lactococcus lactis Ll.LtrB group II intron that retain mobility in vivo. *BMC Molecular Biology*, **2002**, 3, 17	4.5	12
2	Group II introns as controllable gene targeting vectors for genetic manipulation of bacteria. *Nature Biotechnology*, **2001**, 19, 1162-7	44.5	176
1	Characterization of SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.618 on cell entry, host range, and sensitivity to convalescent plasma and ACE2 decoy receptor		2